Zobrazeno 1 - 10
of 97
pro vyhledávání: '"TA Traina"'
Autor:
Ayca Gucalp, Marcia Edelweiss, S. Patil, Artavazd Arumov, Adriana D. Corben, MM Gounder, Kimberly Feigin, TA Traina
Publikováno v:
Cancer Research. 78:P3-11
Background: The androgen-signaling pathway plays a role in breast cancer (BC) pathogenesis and emerging evidence suggests the androgen receptor (AR) is a therapeutic target. TBCRC011 established safety and efficacy of inhibiting AR with bicalutamide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ca2a3c7309fec295ee1fa52366e2fc9
https://doi.org/10.1158/1538-7445.sabcs17-p3-11-04
https://doi.org/10.1158/1538-7445.sabcs17-p3-11-04
Autor:
TA Traina, ES Baskin-Bey, A Resaul, Aditya Bardia, Anthony D. Elias, Joel R. Eisner, Ayca Gucalp
Publikováno v:
Cancer Research. 78:P5-23
Background: Seviteronel (Sevi), an oral selective CYP17-lyase and AR inhibitor that blocks testosterone and estradiol production whilst competitively antagonizing the AR, is in Ph 2 clinical development for the treatment of advanced prostate and brea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7d11b9d71738ce163aec22c88843c8e
https://doi.org/10.1158/1538-7445.sabcs17-p5-23-04
https://doi.org/10.1158/1538-7445.sabcs17-p5-23-04
Autor:
Lowell L. Hart, Maureen E. Trudeau, Frankie A. Holmes, Laura Biganzoli, TA Traina, D Markova, Vandana G. Abramson, Iulia Cristina Tudor, Ahmad Awada, Patrick G. Morris, L. Gianni, Ayca Gucalp, Steve Chan, EP Winer, R Stewart, Claudio Zamagni, Ian E. Krop, E Barry, D. A. Yardley, Joyce Steinberg, D Wheatley, M.A. Colleoni, J Tarazi, Laura G. Estévez, Lee S. Schwartzberg
Publikováno v:
Cancer Research. 78:GS4-07
Background: The androgen receptor (AR) is expressed in >75% of hormone receptor (HR)+ tumors. AR signaling has been associated with resistance to endocrine therapy (ET). Aromatase inhibitors (AIs) divert estrogen precursors to androgens; in preclinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::652564d84d7818a4c452d73d41d0ceba
https://doi.org/10.1158/1538-7445.sabcs17-gs4-07
https://doi.org/10.1158/1538-7445.sabcs17-gs4-07
Autor:
Monica Fornier, K Jack, Maura N. Dickler, Shanu Modi, Gary A. Ulaner, Clifford A. Hudis, L.M. Smyth, Daniel F. Argolo, Chau T. Dang, Larry Norton, Shari Goldfarb, TA Traina, Tiffany A. Troso-Sandoval, Maxine S. Jochelson, Patricia DeFusco, Ayca Gucalp, Neil M. Iyengar, D. Lake, Komal Jhaveri, Jasmeet Chadha Singh, J. Baselga
Publikováno v:
Cancer Research. 77:P4-21
Background: The combination of taxanes with trastuzumab (H) and pertuzumab (P) for first line treatment of HER2-positive metastatic breast cancer (MBC) is associated with improved progression-free survival (PFS) and overall survival (OS). Treatment p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc8da711ada4de79a024f322bea4c875
https://doi.org/10.1158/1538-7445.sabcs16-p4-21-34
https://doi.org/10.1158/1538-7445.sabcs16-p4-21-34
Autor:
Haythem Ali, RA Fleming, Joel R. Eisner, William R. Moore, Aditya Bardia, SJ Lemon, Anthony D. Elias, TA Traina, Ayca Gucalp, Michael A. Danso, Nashat Y. Gabrail, Kurman, Noshir Anthony Dacosta, Elizabeth C. Riley
Publikováno v:
Cancer Research. 77:P2-08
Background: Seviteronel (Sevi), a CYP17-lyase (L) inhibitor (reduces testosterone (T) and estradiol (E2) biosynthesis) and a competitive AR antagonist, has activity in castration resistant prostate cancer at a dose of 600mg nightly. Sevi potently inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::203be0d5e94b9d9276cf5e1ed95543b5
https://doi.org/10.1158/1538-7445.sabcs16-p2-08-04
https://doi.org/10.1158/1538-7445.sabcs16-p2-08-04
Autor:
Karen Cadoo, TA Traina, Erhan Berrak, Andrew D. Seidman, Clifford A. Hudis, C Chang, James Song, Peter A. Kaufman
Publikováno v:
Cancer Research. 76:P1-12
Background: Eribulin has demonstrated antitumor activity and significantly improved overall survival (OS) in patients (pts) with heavily pretreated locally advanced/metastatic breast cancer (BC). This trial assessed the feasibility of eribulin as adj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8914ab7adf68fd017b52900a63cbdd04
https://doi.org/10.1158/1538-7445.sabcs15-p1-12-05
https://doi.org/10.1158/1538-7445.sabcs15-p1-12-05
Autor:
Denise A. Yardley, Ian E. Krop, William J. Gradishar, Michael A. Danso, TA Traina, Steve Chan, Foluso O. Ademuyiwa, N Martinez-Janez, Vandana G. Abramson, Joel S. Parker, Clifford A. Hudis, Kathy D. Miller, Iulia Cristina Tudor, Rita Nanda, Laura García-Estévez, Joyce Steinberg, VE Paton, Karen A. Gelmon, L Ma, John Crown, Hirdesh Uppal, Janice F. Eakle, Lee S. Schwartzberg
Publikováno v:
Cancer Research. 76:P3-07
Background: A novel genomic signature that identifies androgen receptor (AR)-driven disease (PREDICT AR) is being developed for its ability to select patients (pts) who may benefit from enzalutamide (ENZA), a potent AR inhibitor.1 In a phase 2 study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a0440ba92b297b2d0e0214cf21c9378
https://doi.org/10.1158/1538-7445.sabcs15-p3-07-25
https://doi.org/10.1158/1538-7445.sabcs15-p3-07-25
Autor:
D Markova, TA Traina, Joyce Steinberg, Lee S. Schwartzberg, Anthony D. Elias, E Kavalerchik, S Stopatschinskaja, Patel, Howard A. Burris, Jacqueline A. Gibbons, Jennifer K. Richer
Publikováno v:
Cancer Research. 76:P1-16
Background: Fulvestrant (FUL), an estrogen receptor (ER) antagonist, is an effective treatment for patients (pts) with hormone receptor-positive (HR+) breast cancer (BC) whose disease has progressed or recurred during previous anti-estrogen therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bd6b3aefe3433070e60037a69c37dc0
https://doi.org/10.1158/1538-7445.sabcs15-p1-16-05
https://doi.org/10.1158/1538-7445.sabcs15-p1-16-05
Autor:
Y-H Im, TA Traina, S-B Kim, Rebecca Dent, Heather L. McArthur, T Creel, Kimberly L. Blackwell, T Tan
Publikováno v:
Cancer Research. 78:OT3-04
Background: Recent data from the OlympiaD study revealed an improvement in response rate and progression-free survival (PFS) with the PARP inhibitor (PARPi) olaparib vs. standard of care chemotherapy in patients with metastatic breast cancer who harb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::287b049bf5eed3b0ea79f9533cc5108b
https://doi.org/10.1158/1538-7445.sabcs17-ot3-04-02
https://doi.org/10.1158/1538-7445.sabcs17-ot3-04-02
Autor:
Rita Nanda, Dafydd G. Thomas, William J. Irvin, Julie R. Nangia, Martha E. Brown, MC Liu, Andres Forero, Maria C. Muñiz, TA Traina, Kimberly Aung, Yufeng Li, Vandana G. Abramson, Kelley M. Kidwell, Nu Lin, Costanza Paoletti, Daniel F. Hayes, Antonio C. Wolff, Anna Maria Storniolo, C. Van Poznak, Christos Vaklavas
Publikováno v:
Cancer Research. 73:P1-04
Background: Circulating Tumor cells (CTCs) are prognostic at baseline and first follow-up in patients with metastatic breast cancer (MBC). Using the most commonly used assay (CellSearch®), we have previously reported the ability to detect apoptotic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc6356a039a614e32c887969a8777e02
https://doi.org/10.1158/0008-5472.sabcs13-p1-04-01
https://doi.org/10.1158/0008-5472.sabcs13-p1-04-01